Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemia
Andreas Burchert(Philipps University of Marburg), Christin Schütz(Philipps University of Marburg), E. Eigendorff(Chinese Academy of Medical Sciences & Peking Union Medical College), Susanne Saußele(University of Mannheim), Florian Finkernagel(Philipps University of Marburg), Stephan Metzelder(Philipps University of Marburg), Rüdiger Hehlmann(Heidelberg University), Jolanta Dengler(Heidelberg University), Tim H. Brümmendorf(Heidelberg University), Sabrina Inselmann(Philipps University of Marburg), Andreas Hochhaus(Jena University Hospital), Cornelia Brendel(Philipps University of Marburg), Thomas Illmer(Center for Systems Biology Dresden), Regina Herbst(Klinikum Chemnitz), Thoralf Lange, Cornelius F. Waller(University Medical Center Freiburg), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Gernot Freunek, Matthias Goebeler(University of Würzburg), A. Neubauer, Martin C. Müller(Universität Hamburg), Christian Dietz(Technische Universität Darmstadt), H. I. Kappe Stefan, Joëlle Guilhot(Inserm), Yu Hung Wang, F.-X. Mahon, Magdalena Huber(Philipps University of Marburg)
RWTH Publications (RWTH Aachen)
January 1, 2016
Cited by 0
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820